CD8A and diffuse large B-cell lymphoma: Inhibiting of RGC32 demonstrated potential therapeutic benefits in DLBCL by reducing cell proliferation, hindering cell cycle progression, impairing DNA damage repair, and increasing CD8+ T lymphocyte infiltration.